Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a beta value of 1.76 and has seen 1.5 million shares traded in the last trading session. The company, currently valued at $1.75B, closed the last trade at $14.72 per share which meant it gained $0.22 on the day or 1.52% during that session. The ARQT stock price is -10.05% off its 52-week high price of $16.20 and 52.51% above the 52-week low of $6.99.
The consensus among analysts is that Arcutis Biotherapeutics Inc (ARQT) is Buy stock at the moment, with a recommendation rating of 1.25. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Sporting 1.52% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ARQT stock price touched $14.72 or saw a rise of 2.52%. Year-to-date, Arcutis Biotherapeutics Inc shares have moved 5.67%, while the 5-day performance has seen it change 7.52%. Over the past 30 days, the shares of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) have changed 11.68%.
Wall Street analysts have a consensus price target for the stock at $19, which means that the shares’ value could jump 22.53% from current levels. The projected low price target is $19.0 while the price target rests at a high of $19.0. In that case, then, we find that the current price level is -29.08% off the targeted high while a plunge would see the stock gain -29.08% from current levels.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
The company’s shares have gained 40.73% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 53.55%.
6 analysts offering their estimates for the company have set an average revenue estimate of 65.13M for the current quarter. 6 have an estimated revenue figure of 72.79M for the next ending quarter. Year-ago sales stood 49.57M and 30.86M respectively for this quarter and the next, and analysts expect sales will grow by 31.40% for the current quarter and 53.55% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -0.98% over the past 5 years.
ARQT Dividends
Arcutis Biotherapeutics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
The top two institutional holders are JENNISON ASSOCIATES LLC with over 11.57 million shares worth more than $107.62 million. As of 2024-06-30, JENNISON ASSOCIATES LLC held 9.3712% of shares outstanding.
The other major institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, with the holding of over 10.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $93.04 million and represent 8.1021% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and PGIM Jennison Small Company Fd . As of Sep 30, 2024 , the former fund manager holds about 3.03% shares in the company for having 3.59 shares of worth $52.84 million while later fund manager owns 3.09 shares of worth $45.41 million as of Dec 31, 2024 , which makes it owner of about 2.60% of company’s outstanding stock.
